Hello, everyone, and nice to see you again. We disappeared yesterday to take our shortest person on a long-overdue roots trip, of sorts, that was an eye-opening experience into how much life has changed for so many in just a few generations. The food was pretty good, too. But now, of course, we have returned to the usual routine of brewing cups of stimulation and foraging for interesting items. And so, time to get cracking. Here are a few tidbits to get you going. Hope your day is smashing and please do keep in touch …

Sanofi (SNY) pledged about $11 million for rebuilding Notre Dame, but reaction has been mixed, Pharmaphorum notes. Although some praised the move, others took issue because the company is not providing money for people affected by the side effects of its Depakine epilepsy drug. The drug and its generics have been linked to severe birth defects in up to 4,100 children in France since it was first marketed there in 1967, and women who took the drug during pregnancy were four times more likely to have babies with malformations, according to French authorities.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy